EUVIMEDEUVIMED entdecken
Crossref

Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease

Ali R Rezai, Pierre-Francois D'Haese, Victor Finomore iD, Jeffrey Carpenter, Manish Ranjan, Kirk Wilhelmsen, Rashi I Mehta, Peng Wang, Umer Najib, Camila Vieira Ligo Teixeira, Tasneem Arsiwala, Abdul Tarabishy iD und 4 weitere

New England Journal of Medicine · 04.01.2024 · 390 (1) · 55-62

DOI: 10.1056/nejmoa2308719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New England Journal of Medicine, erschienen am 04.01.2024. Verfasst von Ali R Rezai und 15 weiteren Autor:innen. Beteiligte Einrichtung: From the Departments of Neurosurgery (A.R.R., P.-F.D., M.R.), Neuroradiology (P.-F.D., J.C., R.I.M., P.W., A.T.), Neuroscience (A.R.R., V.F., C.V.L.T…. Hauptthemen laut MEDLINE: Alzheimer Disease, Blood-Brain Barrier, Ultrasonic Therapy. Die Arbeit wurde bisher 323-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: The Harry T. Mangurian, Jr. Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in patients with Alzheimer's disease. We applied focused ultrasound with each of six monthly aducanumab infusions to temporarily open the blood-brain barrier with the goal of enhancing amyloid removal in selected brain regions in three participants over a period of 6 months. The reduction in the level of Aβ was numerically greater in regions treated with focused ultrasound than in the homologous regions in the contralateral hemisphere that were not treated with focused ultrasound, as measured by fluorine-18 florbetaben positron-emission tomography. Cognitive tests and safety evaluations were conducted over a period of 30 to 180 days after treatment. (Funded by the Harry T. Mangurian, Jr. Foundation and the West Virginia University Rockefeller Neuroscience Institute.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBlood-Brain BarrierUltrasonic TherapyHumansAmyloid beta-PeptidesBrainPositron-Emission TomographyAntibodies, Monoclonal, Humanized

Substanzen

aducanumabAmyloid beta-PeptidesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • From the Departments of Neurosurgery (A.R.R., P.-F.D., M.R.), Neuroradiology (P.-F.D., J.C., R.I.M., P.W., A.T.), Neuroscience (A.R.R., V.F., C.V.L.T., T.A., P.T., M.W.H., R.I.M.), Neurology (K.W., U.N., M.W.H.), and Be…

ORCID-Profile: Victor Finomore, Abdul Tarabishy

Förderung

  • The Harry T. Mangurian, Jr. Foundation

Zitieren

APA

Rezai, A. R., D'Haese, P. F., Finomore, V., Carpenter, J., Ranjan, M., Wilhelmsen, K., Mehta, R. I., Wang, P., Najib, U., Vieira Ligo Teixeira, C., Arsiwala, T., Tarabishy, A., Tirumalai, P., Claassen, D. O., Hodder, S., & Haut, M. W. (2024). Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease. New England Journal of Medicine, 390(1), 55-62. https://doi.org/10.1056/nejmoa2308719

Vancouver

Rezai AR, D'Haese PF, Finomore V, Carpenter J, Ranjan M, Wilhelmsen K, et al. Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease. New England Journal of Medicine. 2024;390(1):55-62. doi:10.1056/nejmoa2308719

BibTeX
@article{Rezai2024,
  author = {Rezai, Ali R and D'Haese, Pierre-Francois and Finomore, Victor and Carpenter, Jeffrey and Ranjan, Manish and Wilhelmsen, Kirk and Mehta, Rashi I and Wang, Peng and Najib, Umer and Vieira Ligo Teixeira, Camila and Arsiwala, Tasneem and Tarabishy, Abdul and Tirumalai, Padmashree and Claassen, Daniel O and Hodder, Sally and Haut, Marc W},
  title = {Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {1},
  pages = {55--62},
  doi = {10.1056/nejmoa2308719}
}
Kostenlos starten →